Navigation Links
Nile Therapeutics Reports 2011 Third Quarter Financial Results
Date:11/14/2011

risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's plans to develop cenderitide in the post-acute setting, the anticipated benefits of cenderitide for patients in the post-acute setting, Nile's plans for further development of cenderitide, Nile's ability to obtain FDA approval of cenderitide in the post-acute setting and Nile's beliefs about the potential impact of a decrease of the ADHF re-hospitalization rate on the quality of life for patients, are forward-looking statements. Forward-looking statements also include statements regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, expected patient enrollment, anticipated benefits of cenderitide, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to obtain additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, the final results of the Phase I trial of cenderitide may not support Nile's preliminary findings, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those d
'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Orexigen® Therapeutics Reports Third Quarter Financial Results
3. Silence Therapeutics Provides Corporate and Development Update
4. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
5. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
6. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
7. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a follow ... service business units, Whitehouse Laboratories is pleased to announce that it has begun construction ... Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, and ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... manufacturer and supplier, announces the launch of their 2nd generation cell therapy POD® ... current miniPOD CT, but it also represents a new POD® design. , ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3
... Surveillance System Detects ... Emerging Pattern, ... hours,on a recent Friday, 20 people arrived, one by one, for ... various,gastrointestinal symptoms, including nausea and diarrhea., A coincidence? Or the ...
... CHAPEL HILL, N.C., May 22 Pharmaceutical and biotech,companies ... Assurance (QA) functions. This benchmarking study will help R&D,Quality ... Optimizing limited QA staff resources so that they have ... Optimizing services in regards to the FDA,s Risk-Bases method ...
... investor ... conference call, ... of BioElectronics Corporation (Pink Sheets: BIEL), the,developer of ActiPatch, an ... delivers pulsed,electromagnetic therapy, today issued the following summary of its ...
Cached Biology Technology:E. coli Outbreak in New Jersey? 2E. coli Outbreak in New Jersey? 3Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry 2BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 2BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 3BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 4BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 5BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 6BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 7BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 8
(Date:7/23/2015)... DUBLIN , July 23, 2015 ... the addition of the "Global Outlook of ... their offering. The global biometrics ... both public and commercial applications owing to the ... will witness a transformation that enhances the growth ...
(Date:7/13/2015)... July 13, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced sampling of ClearPad ® ... driver integration (TDDI) product targeting smartphones and tablets. ... combine Synaptics , best-in-class touch controller IP ... technology developed in the company,s Japan Design Center. ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... is available in French . , Montreal, November ... poisoning, may be a thing of the past. New findings ... Institute for Agronomic Research (INRA), involving the Universit de Montral ... bacterium is able to survive in the competitive environment ...
... WALTHAM, MA November 28, 2010 ... targeted covalent drugs, has published research in ... irreversible inhibition of a viral protease using a ... "Selective Irreversible Inhibition of a Protease by Targeting ...
... the Advancement of Science has chosen Arizona State University,s ... education, to receive the Science Prize for ... prize, established to "encourage innovation and excellence in education, ... by students, teachers, and the public," recognizes the website,s ...
Cached Biology News:Will this be the end of hamburger disease? 2First-ever covalent irreversible inhibition of a protease central to hepatitis C infection 2ASU’s Ask A Biologist website wins prestigious SPORE prize 2ASU’s Ask A Biologist website wins prestigious SPORE prize 3
...
... Although the mixed TAMRA isomers are ... isomers are increasingly preferred for labeling peptides ... in HPLC purification that is often required ... often used than 6-TAMRA for labeling peptides ...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
Alkali soluble casein is the recommended blot blocking reagent for use with the HisTag Monoclonal Antibody (Novagen) on Western blots....
Biology Products: